Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non–Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials

    Zhonghan Zhang
    Zhonghan Zhang
    Xiaodan Huang
    Xiaodan Huang
    Manli Wu
    Manli Wu
    Siyu Miao
    Siyu Miao

    Clinical Lung Cancer, 2017.

    Cited by: 0|Bibtex|Views1|

    Abstract:

    Abstract Background Five major first- and second-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including erlotinib, gefitinib, icotinib, afatinib, and dacomitinib, are currently optional for patients with advanced non–small-cell lung cancer (NSCLC) who harbor EGFR mutations. However, there was no h...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments